This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schröder, C. P. Articles by de Vries, E. G. E. Search for Related Content PubMed PubMed Citation Articles by Schröder, C. P. Articles by de Vries, E. G. E.

Purging of Epithelial Tumor Cells from Peripheral Blood Stem Cells by Means of the Bispecific Antibody BIS-1¹

Division of Medical Oncology [C. P. S., E. G. E. d. V.], and Division of Clinical Immunology [B-J. K., L. F. M. H. d. L.], Department of Internal Medicine, University Hospital Groningen, 9700 RB Groningen, the Netherlands

Peripheral blood stem cell (PBSC) support in breast cancer patients allows high-dose chemotherapy, but tumor cell contamination of the PBSCs is a potential source of relapse. Specific carcinoma cell killing can be obtained by retargeting activated T cells with bispecific antibody BIS-1, directed against epithelial glycoprotein-2 and CD3. To purge epithelial tumor cells from the PBSCs of breast cancer patients, activation of T cells in PBSCs and T-cell retargeting by BIS-1 was studied. PBSCs, obtained by leukapheresis after chemotherapy and recombinant human granulocyte colony-stimulating factor, were cultured in the presence of PBS, interleukin-2, OKT3, or interleukin-2/OKT3 for induction of T-cell activation. Subsequently, lysis of epithelial tumor cell lines by activated T cells of PBSCs in the presence or absence of BIS-1 was assessed with the ⁵¹Cr-release assay or immunocytochemical staining. The effect on PBSC hematopoietic colony formation (HCF) was evaluated by the granulocyte macrophage colony-stimulating units assay. Prior to activation, PBSCs from breast cancer patients contained higher levels of CD8+ T cells than peripheral blood from healthy volunteers (P < 0.05). The potential of PBSCs to sustain tumor cell lysis was increased after all prior activations and was further enhanced by BIS-1. Maximal BIS-1 effect was observed after OKT3 activation of PBSCs for 72 h (P < 0.0005), inducing a >3 log depletion of tumor cells. HCF was not affected by prior OKT3 activation and/or BIS-1. In conclusion, specific tumor cell lysis by PBSCs can be obtained in vitro by OKT3 activation and BIS-1 retargeting of T cells, without affecting HCF. At present, studies are evaluating this format for future clinical application.

This article has been cited by other articles:

				C.P. Schroder, H. Timmer-Bosscha, J.G. Wijchman, L.F.M.H. de Leij, H. Hollema, M.J. Heineman, and E.G.E. de Vries An in vitro model for purging of tumour cells from ovarian tissue Hum. Reprod., May 1, 2004; 19(5): 1069 - 1075. [Abstract] [Full Text] [PDF]

				I. H. N. Wong, J. Chan, J. Wong, and P. K. H. Tam Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1 Clin. Cancer Res., February 1, 2004; 10(3): 994 - 1002. [Abstract] [Full Text] [PDF]

				C. Y. Koh, J. R. Ortaldo, B. R. Blazar, M. Bennett, and W. J. Murphy NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade Blood, December 1, 2003; 102(12): 4067 - 4075. [Abstract] [Full Text] [PDF]